Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes

ilustraciones, diagramas

Autores:
Vallejo Bolaños, Madelyn Guadalupe
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2023
Institución:
Universidad Nacional de Colombia
Repositorio:
Universidad Nacional de Colombia
Idioma:
spa
OAI Identifier:
oai:repositorio.unal.edu.co:unal/84464
Acceso en línea:
https://repositorio.unal.edu.co/handle/unal/84464
https://repositorio.unal.edu.co/
Palabra clave:
610 - Medicina y salud::616 - Enfermedades
Neoplasias Fibroepiteliales
Neoplasias de la mama
Neoplasms, Fibroepithelial
Breast Neoplasms
Neoplasmas
Neoplasms
Mama
Tumor filodes
Nomograma
Criterios AMOS
Breast
Phyllodes tumor
Nomogram
AMOS criteria
Rights
openAccess
License
Reconocimiento 4.0 Internacional
id UNACIONAL2_a8753e3a0abd99a04a0dbbd068e9c053
oai_identifier_str oai:repositorio.unal.edu.co:unal/84464
network_acronym_str UNACIONAL2
network_name_str Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
dc.title.translated.eng.fl_str_mv Application of the AMOS criteria for the histopathological classification of a series of phyllodes tumor cases
title Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
spellingShingle Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
610 - Medicina y salud::616 - Enfermedades
Neoplasias Fibroepiteliales
Neoplasias de la mama
Neoplasms, Fibroepithelial
Breast Neoplasms
Neoplasmas
Neoplasms
Mama
Tumor filodes
Nomograma
Criterios AMOS
Breast
Phyllodes tumor
Nomogram
AMOS criteria
title_short Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
title_full Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
title_fullStr Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
title_full_unstemmed Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
title_sort Aplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodes
dc.creator.fl_str_mv Vallejo Bolaños, Madelyn Guadalupe
dc.contributor.advisor.none.fl_str_mv Acosta Forero, Bernarda Jinneth
dc.contributor.author.none.fl_str_mv Vallejo Bolaños, Madelyn Guadalupe
dc.contributor.researchgroup.spa.fl_str_mv Anatomopatología y Patología Molecular
dc.subject.ddc.spa.fl_str_mv 610 - Medicina y salud::616 - Enfermedades
topic 610 - Medicina y salud::616 - Enfermedades
Neoplasias Fibroepiteliales
Neoplasias de la mama
Neoplasms, Fibroepithelial
Breast Neoplasms
Neoplasmas
Neoplasms
Mama
Tumor filodes
Nomograma
Criterios AMOS
Breast
Phyllodes tumor
Nomogram
AMOS criteria
dc.subject.decs.spa.fl_str_mv Neoplasias Fibroepiteliales
Neoplasias de la mama
dc.subject.decs.eng.fl_str_mv Neoplasms, Fibroepithelial
Breast Neoplasms
dc.subject.lemb.spa.fl_str_mv Neoplasmas
dc.subject.lemb.eng.fl_str_mv Neoplasms
dc.subject.proposal.spa.fl_str_mv Mama
Tumor filodes
Nomograma
Criterios AMOS
dc.subject.proposal.eng.fl_str_mv Breast
Phyllodes tumor
Nomogram
AMOS criteria
description ilustraciones, diagramas
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2023-08-04T18:57:25Z
dc.date.available.none.fl_str_mv 2023-08-04T18:57:25Z
dc.date.issued.none.fl_str_mv 2023-08-03
dc.type.spa.fl_str_mv Trabajo de grado - Especialidad Médica
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.content.spa.fl_str_mv Text
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/TP
format http://purl.org/coar/resource_type/c_7a1f
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unal.edu.co/handle/unal/84464
dc.identifier.instname.spa.fl_str_mv Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv https://repositorio.unal.edu.co/
url https://repositorio.unal.edu.co/handle/unal/84464
https://repositorio.unal.edu.co/
identifier_str_mv Universidad Nacional de Colombia
Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. Fiks A. Cystosarcoma phyllodes of the mammary gland ? muller’s tumor. Virchows
2. Archiv A Pathological Anatomy and Histology. 1981;392(1):1–6.
3. Chua CL, Thomas A. Cystosarcoma phyllodes tumors. Surg Gynecol Obstet. 1988;166(4):302–6
4. Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71(10):3020–4.
5. Tan PH, Thike AA, Tan WJ, Thu MMM, Busmanis I, Li H, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol. 2012;65(1):69–76.
6. Zhou Z-R, Wang C-C, Sun X-J, Yang Z-Z, Chen X-X, Shao Z-M, et al. Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. Cancer Med. 2018;7(4):1030–42.
7. Co M, Chen C, Tsang JY, Tse G, Kwong A. Mammary phyllodes tumour: a 15-year multicentre clinical review. J Clin Pathol. 2018;71(6):493–7.
8. Pimiento JM, Gadgil PV, Santillan AA, Lee MC, Esposito NN, Kiluk JV, et al. Phyllodes tumors: race-related differences. J Am Coll Surg. 2011;213(4):537–42.
9. Rojas R, Gutierrez A. Gutierrez R. Tumor Filodes. Experiencia quirúrgica del Instituto Nacional de Cancerología. Revista Colombiana de Cirugía. 1994;9(3):157–62.
10. Ossa CA. Phyllodes tumor of the breast: a clinicpathologic study of 77 cases in a Hispanic cohort. Colombia Médica. 2015;46(3):104–8.
11. Guio-Ávila JI, Parra-Medina R, Fajardo-Cuellar AM, Velasco-Plazas NS, Skinner R-. Tumor filodes de la mama: experiencia en el diagnóstico, tratamiento y seguimiento de 28 casos en Colombia. Ginecol Obstet Mex. 88(5):283–92.
12. Bonilla-Sepúlveda ÓA. Características clínico-patológicas, tratamiento y pronóstico de tumor filodes en centros de referencia en Medellín, Colombia. Rev peru ginecol obstet. 2021;67(1).
13. Wilsher M, McKessar M, Mak C. Phyllodes tumour of the nipple presenting with nipple discharge. Pathology. 2014;46(5):455–7.
14. Oshida K, Miyauchi M, Yamamoto N, Takeuchi T, Suzuki M, Nagashima T, et al. Phyllodes tumor arising in ectopic breast tissue of the axilla. Breast Cancer. 2003;10(1):82–4.
15. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program: Association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127–33.
16. Cohn-Cedermark G, Rutqvist LE, Rosendahl I, Silfverswärd C. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer. 1991;68(9):2017–22.
17. Lian D, Cheah E,y Tan PH, Thng CH, Tan SM. Phyllodes tumour with intraductal growth: a rare cause of nipple discharge. Histopathology. 2007;50(5):666–9
18. Pacioles T, Seth R, Orellana C, John I, Panuganty V, Dhaliwal R. Malignant phyllodes tumor of the breast presenting with hypoglycemia: a case report and literature review. Cancer Manag Res. 2014;6:467–73.
19. Landrum ML, Ornstein DL. Hypertrophic osteoarthropathy associated with metastatic Phyllodes tumor. Am J Clin Oncol. 2003;26(2):146–50.
20. Gullett NP, Rizzo M, Johnstone PAS. National surgical patterns of care for primary surgery and axillary staging of phyllodes tumors. Breast J. 2009;15(1):41–4.
21. Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 2016;68(1):5–21.
22. Tan H, Zhang S, Liu H, Peng W, Li R, Gu Y, et al. Imaging findings in phyllodes tumors of the breast. Eur J Radiol. 2012;81(1):e62-9.
23. Yilmaz E, Sal S, Lebe B. Differentiation of phyllodes tumors versus fibroadenomas: Mammographic and sonographic features. Acta Radiol. 2002;43(1):34–9.
24. Kalambo M, Adrada BE, Adeyefa MM, Krishnamurthy S, Hess K, Carkaci S, et al. Phyllodes tumor of the breast: Ultrasound-pathology correlation. AJR Am J Roentgenol. 2018;210(4):W173–9.
25. Kamitani T, Matsuo Y, Yabuuchi H, Fujita N, Nagao M, Kawanami S, et al. Differentiation between benign phyllodes tumors and fibroadenomas of the breast on MR imaging. Eur J Radiol. 2014;83(8):1344–9.
26. Rosen PP. Rosen’s Breast Pathology. 5ª edition. Philadelphia: Lippincott; 2020.
27. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency, and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20(34):4621–8.
28. WHO Classification of Tumours Editorial Board. (2019). Breast Tumours: WHO Classification of Tumours (Medicine) (5th ed.). World Health Organization.
29. Co M, Tse GM, Chen C, Wei J, Kwong A. Coexistence of ductal carcinoma within mammary Phyllodes tumor: A review of 557 cases from a 20-year region-wide database in Hong Kong and southern China. Clin Breast Cancer. 2018;18(3):e421–5.
30. Tan P-H, Jayabaskar T, Chuah K-L, Lee H-Y, Tan Y, Hilmy M, et al. Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol. 2005;123(4):529–40.
31. Slodkowska E, Nofech-Mozes S, Xu B, Parra-Herran C, Lu F-I, Raphael S, et al. Fibroepithelial lesions of the breast: a comprehensive morphological and outcome analysis of a large series. Mod Pathol. 2018;31(7):1073–84.
32. Powell CM, Cranor ML, Rosen PP. Multinucleated stromal giant cells in mammary fibroepithelial neoplasms. A study of 11 patients. Arch Pathol Lab Med. 1994;118(9):912–6.
33. Tse GM, Law BK, Chan KF, Mas TK. Multinucleated stromal giant cells in mammary phyllodes tumours. Pathology. 2001;33(2):153–6.
34. Chng TW, Gudi M, Lim SH, Li H, Tan PH. Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours in a large patient cohort. J Clin Pathol. 2018;71(2):125–8.
35. Bacchi CE, Wludarski SC, Lamovec J, Ben Dor D, Ober E, Salviato T, et al. Lipophyllodes of the breast. A reappraisal of fat-rich tumors of the breast based on 22 cases integrated by immunohistochemical study, molecular pathology insights, and clinical follow-up. Ann Diagn Pathol. 2016; 21:1–6.
36. Krings G, Bean GR, Chen Y-Y. Fibroepithelial lesions; The WHO spectrum. Semin Diagn Pathol. 2017;34(5):438–52.
37. Tay TKY, Guan P, Loke BN, Nasir NDM, Rajasegaran V, Thike AA, et al. Molecular insights into paediatric breast fibroepithelial tumours. Histopathology. 2018;73(5):809–18.
38. Tan BY, Tan PH. A diagnostic approach to fibroepithelial breast lesions. Surg Pathol Clin. 2018;11(1):17–42.
39. Lim SZ, Selvarajan S, Thike AA, Nasir NDBM, Tan BKT, Ong KW, et al. Breast sarcomas and malignant phyllodes tumours: comparison of clinicopathological features, treatment strategies, prognostic factors, and outcomes. Breast Cancer Res Treat. 2016;159(2):229–44.
40. Wang F, Jia Y, Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015;45(2):146–52.
41. Yeong J, Thike AA, Young Ng CC, Md Nasir ND, Loh K, Teh BT, et al. A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology. 2017;49(7):786–9.
42. Chia Y, Thike AA, Cheok PY, Yong-Zheng Chong L, Man-Kit Tse G, Tan PH. Stromal keratin expression in phyllodes tumours of the breast: a comparison with other spindle cell breast lesions. J Clin Pathol. 2012;65(4):339–47.
43. Cimino-Mathews A, Sharma R, Illei PB, Vang R, Argani P. A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies. Am J Surg Pathol. 2014;38(12):1689–96.
44. Field AS, Kurtycz DFI, Raymond WA, Schmitt F. The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Analysis and discussion of the response to a web-based survey. Cancer Cytopathol. 2021;129(6):450–9.
45. Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED. Epithelial--stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer. 1992;70(8):2115–20.
46. Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, et al. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol. 2002;196(4):437–44.
47. Sawyer EJ, Hanby AM, Poulsom R, Jeffery R, Gillett CE, Ellis IO, et al. Beta-catenin abnormalities, and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast: Expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas. J Pathol. 2003;200(5):627–32.
48. Tsang JYS, Mendoza P, Lam CCF, Yu AMC, Putti TC, Karim RZ, et al. Involvement of α- and β-catenins and E-cadherin in the development of mammary phyllodes tumours: Wnt pathways in phyllodes tumour. Histopathology. 2012;61(4):667–74.
49. Karim RZ, O’Toole SA, Scolyer RA, Cooper CL, Chan B, Selinger C, et al. Recent insights into the molecular pathogenesis of mammary phyllodes tumours. J Clin Pathol. 2013;66(6):496–505.
50. Tan WJ, Thike AA, Bay BH, Tan PH. Immunohistochemical expression of homeoproteins Six1 and Pax3 in breast phyllodes tumours correlates with histological grade and clinical outcome. Histopathology. 2014;64(6):807–17.
51. Tawasil J, Go EML, Tsang JYS, Ni Y-B, Ko C-W, Tse GM. Associations of epithelial c-kit expression in phyllodes tumours of the breast. J Clin Pathol. 2015;68(10):808–11.
52. Laé M, La Rosa P, Mandel J, Reyal F, Hupé P, Terrier P, et al. Whole-genome profiling helps to classify phyllodes tumours of the breast. J Clin Pathol. 2016;69(12):1081–7.
53. Liu J, Liu X, Feng X, Liu J, Lv S, Zhang W, et al. C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast. Breast Cancer Res Treat. 2015;149(2):395–401.
54. Tan WJ, Thike AA, Tan SY, Tse GM-K, Tan M-H, Bay BH, et al. CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. Mod Pathol. 2015;28(3):352–8.
55. Tan J, Ong CK, Lim WK, Ng CCY, Thike AA, Ng LM, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015;47(11):1341–5.
56. Piscuoglio S, Ng CK, Murray M, Burke KA, Edelweiss M, Geyer FC, et al. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. J Pathol. 2016;238(4):508–18.
57. Hodges KB, Abdul-Karim FW, Wang M, Lopez-Beltran A, Montironi R, Easley S, et al. Evidence for transformation of fibroadenoma of the breast to malignant Phyllodes tumor. Appl Immunohistochem Mol Morphol. 2009;17(4):345–50.
58. Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, et al. Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer. 1995;76(10):1779–85.
59. Pareja F, Geyer FC, Kumar R, Selenica P, Piscuoglio S, Ng CKY, et al. Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. NPJ Breast Cancer. 2017;3:40.
60. Piscuoglio S, Geyer FC, Burke KA, Murray MP, Ng CK, Mota A, et al. Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. NPJ Breast Cancer. 2016;2(1):16035.
61. Tan PH. Fibroepithelial lesions revisited: implications for diagnosis and management. Mod. Pathol. 2021; 34; 15–37.
62. Zhang Y, Kleer CG. Phyllodes tumor of the breast: Histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med. 2016;140(7):665–71.
63. Cimino-Mathews A, Hicks JL, Sharma R, Vang R, Illei PB, De Marzo A, et al. A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. Hum Pathol. 2013;44(11):2494–500. .
64. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, et al. Phyllodes Tumour Consortium. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol. 2008;214(5):533–44.
65. Liu S-Y, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P, et al. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol. 2016;29(9):1012–27.
66. Lissidini G, Mulè A, Santoro A, Papa G, Nicosia L, Cassano E, et al. Malignant phyllodes tumor of the breast: a systematic review. Pathologica. 2022;114(2):111–20.
67. Tsang JYS, Hui Y-K, Lee MA, Lacambra M, Ni Y-B, Cheung S-Y, et al. Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. Sci Rep. 2018;8(1).
68. Tan WJ, Cima I, Choudhury Y, Wei X, Lim JCT, Thike AA, et al. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Res. 2016;18(1).
69. Sim Y, Ng GXP, Ng CCY, Rajasegaran V, Wong SF, Liu W, et al. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. BMC Med Genomics. 2019;12(1):142.
70. Noronha Y, Raza A, Hutchins B, Chase D, Garberoglio C, Chu P, et al. CD34, CD117, and Ki-67 expression in Phyllodes tumor of the breast: An immunohistochemical study of 33 cases. Int J Surg Pathol. 2011;19(2):152–8.
71. Chen CM, Chen CJ, Chang CL, Shyu JS, Hsieh HF, Harn HJ. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res. 2000;94(2):84–91.
72. Moore T, Lee AH. Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast: CD34 and bcl-2 in phyllodes and fibroadenomas. Histopathology. 2001;38(1):62–7.
73. Cheo FF, Tan YB, Tan PH. An update on the classification of phyllodes tumours of the breast. Diagn. Histopathol. 2022; 28; 119–125.
74. Tse GMK, Lee CS, Kung FYL, Scolyer RA, Law BKB, Lau T-S, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol. 2002;118(4):522–6.
75. Shpitz B, Bomstein Y, Sternberg A, Klein E, Tiomkin V, Kaufman A, et al. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. J Surg Oncol. 2002;79(2):86–92.
76. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.
77. Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR. Silencing beta3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2015;75:2316–25.
78. Feng X, Zhao L, Shen H, Liu X, Yang Y, Lv S, et al. Expression of EMT markers and mode of surgery are prognostic in phyllodes tumors of the breast. Oncotarget. 2017;8(20):33365–74.
79. Millar EK, Beretov J, Marr P, Sarris M, Clarke RA, Kearsley JH, et al. Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology. 1999;34(6):491–6.
80. Tan P-H, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol. 2005;18(12):1527–34.
81. Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, et al. Immunohistochemical and molecular markers in breast phyllodes tumors. Appl Immunohistochem Mol Morphol. 2011;19(2):119–25.
82. Kleer CG, Giordano TJ, Braun T, Oberman HA. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Mod Pathol. 2001;14(3):185–90.
83. Tse GMK, Lui PCW, Scolyer RA, Putti TC, Kung FYL, Law BKB, et al. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. Mod Pathol. 2003;16(10):1007–13.
84. Erhan Y, Zekioglu O, Ersoy O, Tugan D, Aydede H, Sakarya A, et al. P53 and ki-67 expression as prognostic factors in cystosarcoma Phyllodes. Breast J. 2002;8(1):38–44.
85. Kuijper A, de Vos RAI, Lagendijk JH, van der Wall E, van Diest PJ. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol. 2005;123(5):690–8
86. Gatalica Z, Finkelstein S, Lucio E, Tawfik O, Palazzo J, Hightower B, et al. P53 protein expression and gene mutation in Phyllodes tumors of the breast. Pathol Res Pract. 2001;197(3):183–7.
87. Yonemori K, Hasegawa T, Shimizu C, Shibata T, Matsumoto K, Kouno T, et al. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract. 2006;202(10):705–12.
88. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med.2006;130(10):1516–21.
89. Dacic S, Kounelis S, Kouri E, Jones MW. Immunohistochemical profile of cystosarcoma Phyllodes of the breast: A study of 23 cases. Breast J. 2002;8(6):376–81.
90. Kocová L, Skálová A, Fakan F, Rousarová M. Phyllodes tumour of the breast: immunohistochemical study of 37 tumours using MIB1 antibody. Pathol Res Pract. 1998;194(2):97–104.
91. Chan Y-J, Chen B-F, Chang C-L, Yang T-L, Fan C-C. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast. J Chin Med Assoc. 2004;67(1):3–8.
92. Ridgway PF, Jacklin RK, Ziprin P, Harbin L, Peck DH, Darzi AW, et al. Perioperative diagnosis of cystosarcoma phyllodes of the breast may be enhanced by MIB-1 index. J Surg Res. 2004;122(1):83–8.
93. Xia L, Huang Q, Nie D, Shi J, Gong M, Wu B, et al. PAX3 is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Brain Res [Internet]. 2013;1521:68–78.
94. Fang W-H, Wang Q, Li H-M, Ahmed M, Kumar P, Kumar S. PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways. J Cell Mol Med. 2014;18(1):38–48.
95. Plummer RS, Shea CR, Nelson M, Powell SK, Freeman DM, Dan CP, et al. PAX3 expression in primary melanomas and nevi. Mod Pathol. 2008;21(5):525–30.
96. Frascella E, Toffolatti L, Rosolen A. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet. 1998;102(2):104–9.
97. Schulte TW, Toretsky JA, Ress E, Helman L, Neckers LM. Expression of PAX3 in Ewing’s sarcoma family of tumors. Biochem Mol Med. 1997;60(2):121–6.
98. L. Zhang, L. Xia, L. Zhao et al., “Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis,” Carcinogenesis, vol. 36, no. 3, pp. 390–399, 2014.
99. Bellezza G, Prosperi E, Del Sordo R, Colella R, Rulli A, Sidoni A. IMP3 is strongly expressed in malignant Phyllodes tumors of the breast: An immunohistochemical study. Int J Surg Pathol. 2016;24(1):37–42.
100. Takizawa K, Yamamoto H, Taguchi K, Ohno S, Tokunaga E, Yamashita N, et al. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast. Hum Pathol. 2016; 55:30–8.
101. Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, et al. Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol. 2013;88(2):427–36.
102. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program: Association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127–33.
103. Jang JH, Choi M-Y, Lee SK, Kim S, Kim J, Lee J, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19(8):2612–7.
104. Moutte A, Chopin N, Faure C, Beurrier F, Ho Quoc C, Guinaudeau F, et al. Surgical management of benign and borderline Phyllodes tumors of the breast. Breast J. 2016;22(5):547–52.
105. Li GZ, Raut CP, Hunt KK, Feng M, Chugh R. Breast sarcomas, Phyllodes tumors, and desmoid tumors: Epidemiology, diagnosis, staging, and histology-specific management considerations. Am Soc Clin Oncol Educ Book. 2021;41(41):390–404.
106. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer. 2000;89(7):1502–11.
107. Moo T-A, Alabdulkareem H, Tam A, Fontanet C, Lu Y, Landers A, et al. Association between recurrence and re-excision for close and positive margins versus observation in patients with benign Phyllodes tumors. Ann Surg Oncol [Internet]. 2017;24(10):3088–92.
108. Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007;14(10):2961–70.
109. Tan, Benjamin Yongcheng et al. “Survey of recurrent diagnostic challenges in breast phyllodes tumours.” Histopathology vol. 82,1 (2023): 95-105.
110. Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol. 2014;21(10):3304–9.
111. Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009;16(8):2288–94.
112. Zeng S, Zhang X, Yang D, Wang X, Ren G. Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis. Mol Clin Oncol. 2015;3(3):663–71.
113. Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast: Chemotherapy for Phyllodes tumors. Breast J. 2007;13(6):551–6.
114. Sapino A, Bosco M, Cassoni P, Castellano I, Arisio R, Cserni G, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol . 2006;19(4):599–606.
115. Tse GMK, Lee CS, Kung FYL, Scolyer RA, Law BKB, Lau T-S, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol. 2002;118(4):522–6.
116. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology (NCCN Guidelines). Soft Tissue Sarcoma. Version 2.2016. Available at: www.nccn.org (Accessed on February 22, 2016).
117. Schwentner L, Kurzeder C, Kreienberg R, Wöckel A. Focus on haematogenous dissemination of the malignant cystosarcoma phylloides: institutional experience. Arch Gynecol Obstet. 2011;283(3):591–6.
118. Koh VCY, Thike AA, Nasir NDM, Yip GWC, Bay BH, Tan PH. Size, and heterologous elements predict metastases in malignant phyllodes tumours of the breast. Virchows Arch. 2018;472(4):615–21.
119. Confavreux C, Lurkin A, Mitton N, Blondet R, Saba C, Ranchère D, et al. Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer. 2006;42(16):2715–21.
120. Pinedo-Vega AD, Orea-Estudillo D, Hernández-Bernal PA, Pérez-Soriano A, Sánchez-Vázquez B, Pinedo-Vega ME. Tumor filodes: experiencia de 12 años en la Unidad de Oncología del Hospital General de Puebla. Ginecol Obstet Mex 2022; 90 (12): 951-958.
121. Ruvalcaba-Limón, Eva et al. “Phyllodes Tumor of the Breast: 307 Treated Cases, the Largest Mexican Experience at a Single Breast Disease Institution.” Iranian journal of pathology vol. 11,4 (2016): 399-408.
122. Meneses, A et al. “Prognostic factors on 45 cases of phyllodes tumors.” Journal of experimental & clinical cancer research : CR vol. 19,1 (2000): 69-73.
123. Aranda FC, Olaya GEJ, Colín VA, Miguel PPS. Tumor phyllodes: experiencia institucional. Ginecol Obstet Mex 2009; 77(12):567-72.
124. Velázquez-Dohorn M, Gamboa-Domínguez A, Medina-Franco H. Phyllodes tumor of the breast: clinicopathologic analysis of 22 cases. Rev Invest Clin 2013; 65(3):214-20.
125. Rodríguez A JC, Gómez A, Rennola A. Tumor filodes de la mama: revisión de 55 casos en el Hospital Oncológico “Padre Machado”. Rev Venez Oncol 2003; 15(1):28-37.
126. Pérez PJA, Sánchez CG, Bohle OJ, Poblete SMT, Hernández HM, Massri ED. Tumor filodes de la mama. Caracterización clínica e histopatológica de 39 casos. Rev Chil Cir 2007; 59(3):185-90.
127.Ibáñez RG, Marambio GA, Jans BJ, Gamboa GJ, Adonis PP, Trewhela NR, et al. Tumor filoides de la mama. Rev Chil Cir 2010; 62(2):119-24.
128. Wei, Yufan et al. “Predicting the recurrence-free survival of phyllodes tumor of the breast: a nomogram based on clinicopathology features, treatment, and surgical margin.” Gland surgery vol. 12,2 (2023): 152-164.
129. Lin C-C, Chang H-W, Lin C-Y, Chiu C-F, Yeh S-P. The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan. Int J Clin Oncol. 2013;18(4):614- 20. doi:10.1007/s10147-012-0442-4
130. Nishimura, Rieko et al. “Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours.” Journal of clinical pathology vol. 67,8 (2014): 748-50. doi:10.1136/jclinpath-2014-202215
131. Chng, Tze Wei et al. “Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours: an Australian cohort.” Journal of clinical pathology vol. 69,12 (2016): 1124-1126. doi:10.1136/jclinpath-2016-203951.
132. Choi, Jung Eun et al. “Recurrence prediction for breast phyllodes tumours: validation of the Singapore nomogram in Korean women.” Journal of clinical pathology vol. 75,3 (2022): 159-163. doi:10.1136/jclinpath-2020-207093.
133. Toussaint A, Piaget-Rossel R, Stormacq C, Mathevet P, Lepigeon K, Taffe P. Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis. Breast Cancer Res. Treat. 2021; 185; 21–37.
134. Lu Y, Chen Y, Zhu L et al. Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: a systematic review and meta-analysis. Oncologia 2019; 26; 1263–1275.
135. Mihai R, Callagy G, Qassid OL et al. Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. Histopathology 2021; 78; 871–881.
136. Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol 2015;16:e173–80.
137. Tsang, Julia Y et al. “Analysis of recurrent molecular alterations in phyllodes tumour of breast: insights into prognosis and pathogenesis.” Pathology vol. 54,6 (2022): 678-685
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Reconocimiento 4.0 Internacional
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Reconocimiento 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 73 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv Bogotá - Medicina - Especialidad en Patología Anatómica y Clínica
dc.publisher.faculty.spa.fl_str_mv Facultad de Medicina
dc.publisher.place.spa.fl_str_mv Bogotá,Colombia
dc.publisher.branch.spa.fl_str_mv Universidad Nacional de Colombia - Sede Bogotá
institution Universidad Nacional de Colombia
bitstream.url.fl_str_mv https://repositorio.unal.edu.co/bitstream/unal/84464/5/license.txt
https://repositorio.unal.edu.co/bitstream/unal/84464/4/1085925944.2023.pdf
https://repositorio.unal.edu.co/bitstream/unal/84464/6/1085925944.2023.pdf.jpg
bitstream.checksum.fl_str_mv eb34b1cf90b7e1103fc9dfd26be24b4a
dcc5356acc9c7e08a2fbc42f368ef2a9
ad6ae5c2aff672202a79d20cb84840da
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv repositorio_nal@unal.edu.co
_version_ 1814089261250510848
spelling Reconocimiento 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Acosta Forero, Bernarda Jinneth5c00c20085cc2446955539fac6cb0aa8Vallejo Bolaños, Madelyn Guadalupe3ff3a0b7bd0eedc23856c1bf0ab1335bAnatomopatología y Patología Molecular2023-08-04T18:57:25Z2023-08-04T18:57:25Z2023-08-03https://repositorio.unal.edu.co/handle/unal/84464Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, diagramasIntroducción: El tumor filodes (TF) pertenece al grupo de las neoplasias fibroepiteliales de la mama, junto con el fibroadenoma (FA), representa entre el 0,3% y el 1% de todos los tumores primarios de la mama. La clasificación de la OMS en benignos, limítrofes y malignos, presenta desafíos inherentes a la reproducibilidad. Se han creado herramientas como el nomograma de Singapur, utilizando los criterios AMOS (atipia estromal, tasa mitótica, sobrecrecimiento estromal y margen quirúrgico) para establecer una clasificación más objetiva, que permita establecer un pronóstico individualizado, con excelente concordancia en la validación en varios países. Objetivos: Describir la distribución por edad, correlacionar los hallazgos macroscópicos e histopatológicos en las categorías de la OMS. Evaluar los criterios AMOS y establecer el puntaje que se correlaciona con cada categoría histopatológica de la OMS. Métodos: Estudio descriptivo, retrospectivo, tomando los casos de TF de la base de datos del proyecto “EXPLORANDO LA PATOLOGÍA MAMARIA A TRAVÉS DE UNA BASE DE DATOS DE UN LABORATORIO DE PATOLOGÍA - Experiencia de 11 años 2008-2019”. Se incluyeron 53 casos, de los cuales se recopilaron los datos de los reportes de patología, y fueron analizados utilizando estadística descriptiva. Además, se estableció el valor de los criterios AMOS en cada caso. Resultados: La edad media de presentación fue de 43.3 años (15-68), el tamaño medio fue de 3.6 cm (0.8-12). Según la clasificación histológica de la OMS, el más frecuente fue el tipo benigno con 51% (n:27), seguido del limítrofe con 47%(n:25) y maligno con 2% (n:1). Todos fueron unifocales, ninguno presentó características degenerativas ni presencia de elementos heterólogos malignos. Los criterios AMOS en los TF benignos, limítrofes y malignos tuvieron un rango entre 0-41, 11-65 y 38 respectivamente. Y al aplicar los criterios AMOS excluyendo el margen quirúrgico se encontraron rangos de 0-1, 1 y 25 y 38 para cada categoría en orden ascendente, respetivamente. Únicamente este último parámetro tuvo una diferencia estadísticamente significativa al relacionarlo con las categorías de la OMS. Conclusión: el valor de los criterios AMOS es útil para realizar una clasificación más objetiva del TF que la establecida en las categorías benigno, limítrofe y maligno por el grupo de trabajo de la OMS. (Texto tomado de la fuente)Introduction: Phyllodes tumor (FT) belongs to the group of fibroepithelial neoplasms of the breast, together with fibroadenoma (FA), it represents between 0.3% and 1% of all primary tumors of the breast. The WHO classification into benign, borderline, and malignant presents inherent reproducibility challenges. Tools such as the Singapore nomogram have been created, using the AMOS criteria (stromal atypia, mitotic rate, stromal overgrowth, and surgical margin) to establish a more objective classification, which allows establishing an individualized prognosis, with excellent concordance in validation in several countries. Objectives: Describe the distribution by age, correlate the macroscopic and histopathological findings in the WHO categories. To evaluate the AMOS criteria and establish the score that correlates with each histopathological category of the WHO. Methods: Descriptive, retrospective study, taking TF cases from the database of the project “EXPLORANDO LA PATOLOGÍA MAMARIA A TRAVÉS DE UNA BASE DE DATOS DE UN LABORATORIO DE PATOLOGÍA - Experiencia de 11 años 2008-2019”. 53 cases were included, of which the data from the pathology reports were collected and analyzed using descriptive statistics. In addition, the value of the AMOS criteria was established in each case. Results: The mean age of presentation was 43.3 years (15-68), the mean size was 3.6 cm (0.8-12). According to the histological classification of the WHO, the most frequent was the benign type with 51% (n:27), followed by borderline with 47% (n:25) and malignant with 2% (n:1). All were unifocal, none presented degenerative characteristics or the presence of malignant heterologous elements. AMOS criteria in benign, borderline, and malignant TFs ranged from 0-41, 11-65, and 38, respectively. And when applying the AMOS criteria excluding the surgical margin, ranges of 0-1, 1 and 25 and 38 were found for each category in ascending order, respectively. Only this last parameter had a statistically significant difference when related to the category of the WHO. Conclusion: the value of the AMOS criteria is useful for carrying out a more objective classification of FT than that established in the benign, borderline and malignant categories by the WHO working group.Especialidades MédicasEspecialista en Patología Anatómica y Clínica73 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Especialidad en Patología Anatómica y ClínicaFacultad de MedicinaBogotá,ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y salud::616 - EnfermedadesNeoplasias FibroepitelialesNeoplasias de la mamaNeoplasms, FibroepithelialBreast NeoplasmsNeoplasmasNeoplasmsMamaTumor filodesNomogramaCriterios AMOSBreastPhyllodes tumorNomogramAMOS criteriaAplicación de los criterios AMOS para la clasificación histopatológica de una serie de casos de tumor filodesApplication of the AMOS criteria for the histopathological classification of a series of phyllodes tumor casesTrabajo de grado - Especialidad Médicainfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_7a1fTexthttp://purl.org/redcol/resource_type/TP1. Fiks A. Cystosarcoma phyllodes of the mammary gland ? muller’s tumor. Virchows2. Archiv A Pathological Anatomy and Histology. 1981;392(1):1–6.3. Chua CL, Thomas A. Cystosarcoma phyllodes tumors. Surg Gynecol Obstet. 1988;166(4):302–64. Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71(10):3020–4.5. Tan PH, Thike AA, Tan WJ, Thu MMM, Busmanis I, Li H, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol. 2012;65(1):69–76.6. Zhou Z-R, Wang C-C, Sun X-J, Yang Z-Z, Chen X-X, Shao Z-M, et al. Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. Cancer Med. 2018;7(4):1030–42.7. Co M, Chen C, Tsang JY, Tse G, Kwong A. Mammary phyllodes tumour: a 15-year multicentre clinical review. J Clin Pathol. 2018;71(6):493–7.8. Pimiento JM, Gadgil PV, Santillan AA, Lee MC, Esposito NN, Kiluk JV, et al. Phyllodes tumors: race-related differences. J Am Coll Surg. 2011;213(4):537–42.9. Rojas R, Gutierrez A. Gutierrez R. Tumor Filodes. Experiencia quirúrgica del Instituto Nacional de Cancerología. Revista Colombiana de Cirugía. 1994;9(3):157–62.10. Ossa CA. Phyllodes tumor of the breast: a clinicpathologic study of 77 cases in a Hispanic cohort. Colombia Médica. 2015;46(3):104–8.11. Guio-Ávila JI, Parra-Medina R, Fajardo-Cuellar AM, Velasco-Plazas NS, Skinner R-. Tumor filodes de la mama: experiencia en el diagnóstico, tratamiento y seguimiento de 28 casos en Colombia. Ginecol Obstet Mex. 88(5):283–92.12. Bonilla-Sepúlveda ÓA. Características clínico-patológicas, tratamiento y pronóstico de tumor filodes en centros de referencia en Medellín, Colombia. Rev peru ginecol obstet. 2021;67(1).13. Wilsher M, McKessar M, Mak C. Phyllodes tumour of the nipple presenting with nipple discharge. Pathology. 2014;46(5):455–7.14. Oshida K, Miyauchi M, Yamamoto N, Takeuchi T, Suzuki M, Nagashima T, et al. Phyllodes tumor arising in ectopic breast tissue of the axilla. Breast Cancer. 2003;10(1):82–4.15. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program: Association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127–33.16. Cohn-Cedermark G, Rutqvist LE, Rosendahl I, Silfverswärd C. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer. 1991;68(9):2017–22.17. Lian D, Cheah E,y Tan PH, Thng CH, Tan SM. Phyllodes tumour with intraductal growth: a rare cause of nipple discharge. Histopathology. 2007;50(5):666–918. Pacioles T, Seth R, Orellana C, John I, Panuganty V, Dhaliwal R. Malignant phyllodes tumor of the breast presenting with hypoglycemia: a case report and literature review. Cancer Manag Res. 2014;6:467–73.19. Landrum ML, Ornstein DL. Hypertrophic osteoarthropathy associated with metastatic Phyllodes tumor. Am J Clin Oncol. 2003;26(2):146–50.20. Gullett NP, Rizzo M, Johnstone PAS. National surgical patterns of care for primary surgery and axillary staging of phyllodes tumors. Breast J. 2009;15(1):41–4.21. Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 2016;68(1):5–21.22. Tan H, Zhang S, Liu H, Peng W, Li R, Gu Y, et al. Imaging findings in phyllodes tumors of the breast. Eur J Radiol. 2012;81(1):e62-9.23. Yilmaz E, Sal S, Lebe B. Differentiation of phyllodes tumors versus fibroadenomas: Mammographic and sonographic features. Acta Radiol. 2002;43(1):34–9.24. Kalambo M, Adrada BE, Adeyefa MM, Krishnamurthy S, Hess K, Carkaci S, et al. Phyllodes tumor of the breast: Ultrasound-pathology correlation. AJR Am J Roentgenol. 2018;210(4):W173–9.25. Kamitani T, Matsuo Y, Yabuuchi H, Fujita N, Nagao M, Kawanami S, et al. Differentiation between benign phyllodes tumors and fibroadenomas of the breast on MR imaging. Eur J Radiol. 2014;83(8):1344–9.26. Rosen PP. Rosen’s Breast Pathology. 5ª edition. Philadelphia: Lippincott; 2020.27. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency, and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20(34):4621–8.28. WHO Classification of Tumours Editorial Board. (2019). Breast Tumours: WHO Classification of Tumours (Medicine) (5th ed.). World Health Organization.29. Co M, Tse GM, Chen C, Wei J, Kwong A. Coexistence of ductal carcinoma within mammary Phyllodes tumor: A review of 557 cases from a 20-year region-wide database in Hong Kong and southern China. Clin Breast Cancer. 2018;18(3):e421–5.30. Tan P-H, Jayabaskar T, Chuah K-L, Lee H-Y, Tan Y, Hilmy M, et al. Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol. 2005;123(4):529–40.31. Slodkowska E, Nofech-Mozes S, Xu B, Parra-Herran C, Lu F-I, Raphael S, et al. Fibroepithelial lesions of the breast: a comprehensive morphological and outcome analysis of a large series. Mod Pathol. 2018;31(7):1073–84.32. Powell CM, Cranor ML, Rosen PP. Multinucleated stromal giant cells in mammary fibroepithelial neoplasms. A study of 11 patients. Arch Pathol Lab Med. 1994;118(9):912–6.33. Tse GM, Law BK, Chan KF, Mas TK. Multinucleated stromal giant cells in mammary phyllodes tumours. Pathology. 2001;33(2):153–6.34. Chng TW, Gudi M, Lim SH, Li H, Tan PH. Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours in a large patient cohort. J Clin Pathol. 2018;71(2):125–8.35. Bacchi CE, Wludarski SC, Lamovec J, Ben Dor D, Ober E, Salviato T, et al. Lipophyllodes of the breast. A reappraisal of fat-rich tumors of the breast based on 22 cases integrated by immunohistochemical study, molecular pathology insights, and clinical follow-up. Ann Diagn Pathol. 2016; 21:1–6.36. Krings G, Bean GR, Chen Y-Y. Fibroepithelial lesions; The WHO spectrum. Semin Diagn Pathol. 2017;34(5):438–52.37. Tay TKY, Guan P, Loke BN, Nasir NDM, Rajasegaran V, Thike AA, et al. Molecular insights into paediatric breast fibroepithelial tumours. Histopathology. 2018;73(5):809–18.38. Tan BY, Tan PH. A diagnostic approach to fibroepithelial breast lesions. Surg Pathol Clin. 2018;11(1):17–42.39. Lim SZ, Selvarajan S, Thike AA, Nasir NDBM, Tan BKT, Ong KW, et al. Breast sarcomas and malignant phyllodes tumours: comparison of clinicopathological features, treatment strategies, prognostic factors, and outcomes. Breast Cancer Res Treat. 2016;159(2):229–44.40. Wang F, Jia Y, Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015;45(2):146–52.41. Yeong J, Thike AA, Young Ng CC, Md Nasir ND, Loh K, Teh BT, et al. A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology. 2017;49(7):786–9.42. Chia Y, Thike AA, Cheok PY, Yong-Zheng Chong L, Man-Kit Tse G, Tan PH. Stromal keratin expression in phyllodes tumours of the breast: a comparison with other spindle cell breast lesions. J Clin Pathol. 2012;65(4):339–47.43. Cimino-Mathews A, Sharma R, Illei PB, Vang R, Argani P. A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies. Am J Surg Pathol. 2014;38(12):1689–96.44. Field AS, Kurtycz DFI, Raymond WA, Schmitt F. The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Analysis and discussion of the response to a web-based survey. Cancer Cytopathol. 2021;129(6):450–9.45. Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED. Epithelial--stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer. 1992;70(8):2115–20.46. Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, et al. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol. 2002;196(4):437–44.47. Sawyer EJ, Hanby AM, Poulsom R, Jeffery R, Gillett CE, Ellis IO, et al. Beta-catenin abnormalities, and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast: Expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas. J Pathol. 2003;200(5):627–32.48. Tsang JYS, Mendoza P, Lam CCF, Yu AMC, Putti TC, Karim RZ, et al. Involvement of α- and β-catenins and E-cadherin in the development of mammary phyllodes tumours: Wnt pathways in phyllodes tumour. Histopathology. 2012;61(4):667–74.49. Karim RZ, O’Toole SA, Scolyer RA, Cooper CL, Chan B, Selinger C, et al. Recent insights into the molecular pathogenesis of mammary phyllodes tumours. J Clin Pathol. 2013;66(6):496–505.50. Tan WJ, Thike AA, Bay BH, Tan PH. Immunohistochemical expression of homeoproteins Six1 and Pax3 in breast phyllodes tumours correlates with histological grade and clinical outcome. Histopathology. 2014;64(6):807–17.51. Tawasil J, Go EML, Tsang JYS, Ni Y-B, Ko C-W, Tse GM. Associations of epithelial c-kit expression in phyllodes tumours of the breast. J Clin Pathol. 2015;68(10):808–11.52. Laé M, La Rosa P, Mandel J, Reyal F, Hupé P, Terrier P, et al. Whole-genome profiling helps to classify phyllodes tumours of the breast. J Clin Pathol. 2016;69(12):1081–7.53. Liu J, Liu X, Feng X, Liu J, Lv S, Zhang W, et al. C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast. Breast Cancer Res Treat. 2015;149(2):395–401.54. Tan WJ, Thike AA, Tan SY, Tse GM-K, Tan M-H, Bay BH, et al. CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. Mod Pathol. 2015;28(3):352–8.55. Tan J, Ong CK, Lim WK, Ng CCY, Thike AA, Ng LM, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015;47(11):1341–5.56. Piscuoglio S, Ng CK, Murray M, Burke KA, Edelweiss M, Geyer FC, et al. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. J Pathol. 2016;238(4):508–18.57. Hodges KB, Abdul-Karim FW, Wang M, Lopez-Beltran A, Montironi R, Easley S, et al. Evidence for transformation of fibroadenoma of the breast to malignant Phyllodes tumor. Appl Immunohistochem Mol Morphol. 2009;17(4):345–50.58. Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, et al. Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer. 1995;76(10):1779–85.59. Pareja F, Geyer FC, Kumar R, Selenica P, Piscuoglio S, Ng CKY, et al. Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. NPJ Breast Cancer. 2017;3:40.60. Piscuoglio S, Geyer FC, Burke KA, Murray MP, Ng CK, Mota A, et al. Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. NPJ Breast Cancer. 2016;2(1):16035.61. Tan PH. Fibroepithelial lesions revisited: implications for diagnosis and management. Mod. Pathol. 2021; 34; 15–37.62. Zhang Y, Kleer CG. Phyllodes tumor of the breast: Histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med. 2016;140(7):665–71.63. Cimino-Mathews A, Hicks JL, Sharma R, Vang R, Illei PB, De Marzo A, et al. A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. Hum Pathol. 2013;44(11):2494–500. .64. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, et al. Phyllodes Tumour Consortium. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol. 2008;214(5):533–44.65. Liu S-Y, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P, et al. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol. 2016;29(9):1012–27.66. Lissidini G, Mulè A, Santoro A, Papa G, Nicosia L, Cassano E, et al. Malignant phyllodes tumor of the breast: a systematic review. Pathologica. 2022;114(2):111–20.67. Tsang JYS, Hui Y-K, Lee MA, Lacambra M, Ni Y-B, Cheung S-Y, et al. Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. Sci Rep. 2018;8(1).68. Tan WJ, Cima I, Choudhury Y, Wei X, Lim JCT, Thike AA, et al. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Res. 2016;18(1).69. Sim Y, Ng GXP, Ng CCY, Rajasegaran V, Wong SF, Liu W, et al. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. BMC Med Genomics. 2019;12(1):142.70. Noronha Y, Raza A, Hutchins B, Chase D, Garberoglio C, Chu P, et al. CD34, CD117, and Ki-67 expression in Phyllodes tumor of the breast: An immunohistochemical study of 33 cases. Int J Surg Pathol. 2011;19(2):152–8.71. Chen CM, Chen CJ, Chang CL, Shyu JS, Hsieh HF, Harn HJ. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res. 2000;94(2):84–91.72. Moore T, Lee AH. Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast: CD34 and bcl-2 in phyllodes and fibroadenomas. Histopathology. 2001;38(1):62–7.73. Cheo FF, Tan YB, Tan PH. An update on the classification of phyllodes tumours of the breast. Diagn. Histopathol. 2022; 28; 119–125.74. Tse GMK, Lee CS, Kung FYL, Scolyer RA, Law BKB, Lau T-S, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol. 2002;118(4):522–6.75. Shpitz B, Bomstein Y, Sternberg A, Klein E, Tiomkin V, Kaufman A, et al. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. J Surg Oncol. 2002;79(2):86–92.76. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.77. Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR. Silencing beta3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2015;75:2316–25.78. Feng X, Zhao L, Shen H, Liu X, Yang Y, Lv S, et al. Expression of EMT markers and mode of surgery are prognostic in phyllodes tumors of the breast. Oncotarget. 2017;8(20):33365–74.79. Millar EK, Beretov J, Marr P, Sarris M, Clarke RA, Kearsley JH, et al. Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology. 1999;34(6):491–6.80. Tan P-H, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol. 2005;18(12):1527–34.81. Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, et al. Immunohistochemical and molecular markers in breast phyllodes tumors. Appl Immunohistochem Mol Morphol. 2011;19(2):119–25.82. Kleer CG, Giordano TJ, Braun T, Oberman HA. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Mod Pathol. 2001;14(3):185–90.83. Tse GMK, Lui PCW, Scolyer RA, Putti TC, Kung FYL, Law BKB, et al. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. Mod Pathol. 2003;16(10):1007–13.84. Erhan Y, Zekioglu O, Ersoy O, Tugan D, Aydede H, Sakarya A, et al. P53 and ki-67 expression as prognostic factors in cystosarcoma Phyllodes. Breast J. 2002;8(1):38–44.85. Kuijper A, de Vos RAI, Lagendijk JH, van der Wall E, van Diest PJ. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol. 2005;123(5):690–886. Gatalica Z, Finkelstein S, Lucio E, Tawfik O, Palazzo J, Hightower B, et al. P53 protein expression and gene mutation in Phyllodes tumors of the breast. Pathol Res Pract. 2001;197(3):183–7.87. Yonemori K, Hasegawa T, Shimizu C, Shibata T, Matsumoto K, Kouno T, et al. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract. 2006;202(10):705–12.88. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med.2006;130(10):1516–21.89. Dacic S, Kounelis S, Kouri E, Jones MW. Immunohistochemical profile of cystosarcoma Phyllodes of the breast: A study of 23 cases. Breast J. 2002;8(6):376–81.90. Kocová L, Skálová A, Fakan F, Rousarová M. Phyllodes tumour of the breast: immunohistochemical study of 37 tumours using MIB1 antibody. Pathol Res Pract. 1998;194(2):97–104.91. Chan Y-J, Chen B-F, Chang C-L, Yang T-L, Fan C-C. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast. J Chin Med Assoc. 2004;67(1):3–8.92. Ridgway PF, Jacklin RK, Ziprin P, Harbin L, Peck DH, Darzi AW, et al. Perioperative diagnosis of cystosarcoma phyllodes of the breast may be enhanced by MIB-1 index. J Surg Res. 2004;122(1):83–8.93. Xia L, Huang Q, Nie D, Shi J, Gong M, Wu B, et al. PAX3 is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Brain Res [Internet]. 2013;1521:68–78.94. Fang W-H, Wang Q, Li H-M, Ahmed M, Kumar P, Kumar S. PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways. J Cell Mol Med. 2014;18(1):38–48.95. Plummer RS, Shea CR, Nelson M, Powell SK, Freeman DM, Dan CP, et al. PAX3 expression in primary melanomas and nevi. Mod Pathol. 2008;21(5):525–30.96. Frascella E, Toffolatti L, Rosolen A. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet. 1998;102(2):104–9.97. Schulte TW, Toretsky JA, Ress E, Helman L, Neckers LM. Expression of PAX3 in Ewing’s sarcoma family of tumors. Biochem Mol Med. 1997;60(2):121–6.98. L. Zhang, L. Xia, L. Zhao et al., “Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis,” Carcinogenesis, vol. 36, no. 3, pp. 390–399, 2014.99. Bellezza G, Prosperi E, Del Sordo R, Colella R, Rulli A, Sidoni A. IMP3 is strongly expressed in malignant Phyllodes tumors of the breast: An immunohistochemical study. Int J Surg Pathol. 2016;24(1):37–42.100. Takizawa K, Yamamoto H, Taguchi K, Ohno S, Tokunaga E, Yamashita N, et al. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast. Hum Pathol. 2016; 55:30–8.101. Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, et al. Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol. 2013;88(2):427–36.102. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program: Association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127–33.103. Jang JH, Choi M-Y, Lee SK, Kim S, Kim J, Lee J, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19(8):2612–7.104. Moutte A, Chopin N, Faure C, Beurrier F, Ho Quoc C, Guinaudeau F, et al. Surgical management of benign and borderline Phyllodes tumors of the breast. Breast J. 2016;22(5):547–52.105. Li GZ, Raut CP, Hunt KK, Feng M, Chugh R. Breast sarcomas, Phyllodes tumors, and desmoid tumors: Epidemiology, diagnosis, staging, and histology-specific management considerations. Am Soc Clin Oncol Educ Book. 2021;41(41):390–404.106. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer. 2000;89(7):1502–11.107. Moo T-A, Alabdulkareem H, Tam A, Fontanet C, Lu Y, Landers A, et al. Association between recurrence and re-excision for close and positive margins versus observation in patients with benign Phyllodes tumors. Ann Surg Oncol [Internet]. 2017;24(10):3088–92.108. Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007;14(10):2961–70.109. Tan, Benjamin Yongcheng et al. “Survey of recurrent diagnostic challenges in breast phyllodes tumours.” Histopathology vol. 82,1 (2023): 95-105.110. Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol. 2014;21(10):3304–9.111. Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009;16(8):2288–94.112. Zeng S, Zhang X, Yang D, Wang X, Ren G. Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis. Mol Clin Oncol. 2015;3(3):663–71.113. Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast: Chemotherapy for Phyllodes tumors. Breast J. 2007;13(6):551–6.114. Sapino A, Bosco M, Cassoni P, Castellano I, Arisio R, Cserni G, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol . 2006;19(4):599–606.115. Tse GMK, Lee CS, Kung FYL, Scolyer RA, Law BKB, Lau T-S, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol. 2002;118(4):522–6.116. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology (NCCN Guidelines). Soft Tissue Sarcoma. Version 2.2016. Available at: www.nccn.org (Accessed on February 22, 2016).117. Schwentner L, Kurzeder C, Kreienberg R, Wöckel A. Focus on haematogenous dissemination of the malignant cystosarcoma phylloides: institutional experience. Arch Gynecol Obstet. 2011;283(3):591–6.118. Koh VCY, Thike AA, Nasir NDM, Yip GWC, Bay BH, Tan PH. Size, and heterologous elements predict metastases in malignant phyllodes tumours of the breast. Virchows Arch. 2018;472(4):615–21.119. Confavreux C, Lurkin A, Mitton N, Blondet R, Saba C, Ranchère D, et al. Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer. 2006;42(16):2715–21.120. Pinedo-Vega AD, Orea-Estudillo D, Hernández-Bernal PA, Pérez-Soriano A, Sánchez-Vázquez B, Pinedo-Vega ME. Tumor filodes: experiencia de 12 años en la Unidad de Oncología del Hospital General de Puebla. Ginecol Obstet Mex 2022; 90 (12): 951-958.121. Ruvalcaba-Limón, Eva et al. “Phyllodes Tumor of the Breast: 307 Treated Cases, the Largest Mexican Experience at a Single Breast Disease Institution.” Iranian journal of pathology vol. 11,4 (2016): 399-408.122. Meneses, A et al. “Prognostic factors on 45 cases of phyllodes tumors.” Journal of experimental & clinical cancer research : CR vol. 19,1 (2000): 69-73.123. Aranda FC, Olaya GEJ, Colín VA, Miguel PPS. Tumor phyllodes: experiencia institucional. Ginecol Obstet Mex 2009; 77(12):567-72.124. Velázquez-Dohorn M, Gamboa-Domínguez A, Medina-Franco H. Phyllodes tumor of the breast: clinicopathologic analysis of 22 cases. Rev Invest Clin 2013; 65(3):214-20.125. Rodríguez A JC, Gómez A, Rennola A. Tumor filodes de la mama: revisión de 55 casos en el Hospital Oncológico “Padre Machado”. Rev Venez Oncol 2003; 15(1):28-37.126. Pérez PJA, Sánchez CG, Bohle OJ, Poblete SMT, Hernández HM, Massri ED. Tumor filodes de la mama. Caracterización clínica e histopatológica de 39 casos. Rev Chil Cir 2007; 59(3):185-90.127.Ibáñez RG, Marambio GA, Jans BJ, Gamboa GJ, Adonis PP, Trewhela NR, et al. Tumor filoides de la mama. Rev Chil Cir 2010; 62(2):119-24.128. Wei, Yufan et al. “Predicting the recurrence-free survival of phyllodes tumor of the breast: a nomogram based on clinicopathology features, treatment, and surgical margin.” Gland surgery vol. 12,2 (2023): 152-164.129. Lin C-C, Chang H-W, Lin C-Y, Chiu C-F, Yeh S-P. The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan. Int J Clin Oncol. 2013;18(4):614- 20. doi:10.1007/s10147-012-0442-4130. Nishimura, Rieko et al. “Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours.” Journal of clinical pathology vol. 67,8 (2014): 748-50. doi:10.1136/jclinpath-2014-202215131. Chng, Tze Wei et al. “Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours: an Australian cohort.” Journal of clinical pathology vol. 69,12 (2016): 1124-1126. doi:10.1136/jclinpath-2016-203951.132. Choi, Jung Eun et al. “Recurrence prediction for breast phyllodes tumours: validation of the Singapore nomogram in Korean women.” Journal of clinical pathology vol. 75,3 (2022): 159-163. doi:10.1136/jclinpath-2020-207093.133. Toussaint A, Piaget-Rossel R, Stormacq C, Mathevet P, Lepigeon K, Taffe P. Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis. Breast Cancer Res. Treat. 2021; 185; 21–37.134. Lu Y, Chen Y, Zhu L et al. Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: a systematic review and meta-analysis. Oncologia 2019; 26; 1263–1275.135. Mihai R, Callagy G, Qassid OL et al. Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. Histopathology 2021; 78; 871–881.136. Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol 2015;16:e173–80.137. Tsang, Julia Y et al. “Analysis of recurrent molecular alterations in phyllodes tumour of breast: insights into prognosis and pathogenesis.” Pathology vol. 54,6 (2022): 678-685EstudiantesInvestigadoresLICENSElicense.txtlicense.txttext/plain; charset=utf-85879https://repositorio.unal.edu.co/bitstream/unal/84464/5/license.txteb34b1cf90b7e1103fc9dfd26be24b4aMD55ORIGINAL1085925944.2023.pdf1085925944.2023.pdfTrabajo de grado - Especialista en Patología Anatómica y Clínicaapplication/pdf1840448https://repositorio.unal.edu.co/bitstream/unal/84464/4/1085925944.2023.pdfdcc5356acc9c7e08a2fbc42f368ef2a9MD54THUMBNAIL1085925944.2023.pdf.jpg1085925944.2023.pdf.jpgGenerated Thumbnailimage/jpeg4942https://repositorio.unal.edu.co/bitstream/unal/84464/6/1085925944.2023.pdf.jpgad6ae5c2aff672202a79d20cb84840daMD56unal/84464oai:repositorio.unal.edu.co:unal/844642024-08-18 23:13:02.252Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.coUEFSVEUgMS4gVMOJUk1JTk9TIERFIExBIExJQ0VOQ0lBIFBBUkEgUFVCTElDQUNJw5NOIERFIE9CUkFTIEVOIEVMIFJFUE9TSVRPUklPIElOU1RJVFVDSU9OQUwgVU5BTC4KCkxvcyBhdXRvcmVzIHkvbyB0aXR1bGFyZXMgZGUgbG9zIGRlcmVjaG9zIHBhdHJpbW9uaWFsZXMgZGUgYXV0b3IsIGNvbmZpZXJlbiBhIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHVuYSBsaWNlbmNpYSBubyBleGNsdXNpdmEsIGxpbWl0YWRhIHkgZ3JhdHVpdGEgc29icmUgbGEgb2JyYSBxdWUgc2UgaW50ZWdyYSBlbiBlbCBSZXBvc2l0b3JpbyBJbnN0aXR1Y2lvbmFsLCBiYWpvIGxvcyBzaWd1aWVudGVzIHTDqXJtaW5vczoKCgphKQlMb3MgYXV0b3JlcyB5L28gbG9zIHRpdHVsYXJlcyBkZSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciBzb2JyZSBsYSBvYnJhIGNvbmZpZXJlbiBhIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHVuYSBsaWNlbmNpYSBubyBleGNsdXNpdmEgcGFyYSByZWFsaXphciBsb3Mgc2lndWllbnRlcyBhY3RvcyBzb2JyZSBsYSBvYnJhOiBpKSByZXByb2R1Y2lyIGxhIG9icmEgZGUgbWFuZXJhIGRpZ2l0YWwsIHBlcm1hbmVudGUgbyB0ZW1wb3JhbCwgaW5jbHV5ZW5kbyBlbCBhbG1hY2VuYW1pZW50byBlbGVjdHLDs25pY28sIGFzw60gY29tbyBjb252ZXJ0aXIgZWwgZG9jdW1lbnRvIGVuIGVsIGN1YWwgc2UgZW5jdWVudHJhIGNvbnRlbmlkYSBsYSBvYnJhIGEgY3VhbHF1aWVyIG1lZGlvIG8gZm9ybWF0byBleGlzdGVudGUgYSBsYSBmZWNoYSBkZSBsYSBzdXNjcmlwY2nDs24gZGUgbGEgcHJlc2VudGUgbGljZW5jaWEsIHkgaWkpIGNvbXVuaWNhciBhbCBww7pibGljbyBsYSBvYnJhIHBvciBjdWFscXVpZXIgbWVkaW8gbyBwcm9jZWRpbWllbnRvLCBlbiBtZWRpb3MgYWzDoW1icmljb3MgbyBpbmFsw6FtYnJpY29zLCBpbmNsdXllbmRvIGxhIHB1ZXN0YSBhIGRpc3Bvc2ljacOzbiBlbiBhY2Nlc28gYWJpZXJ0by4gQWRpY2lvbmFsIGEgbG8gYW50ZXJpb3IsIGVsIGF1dG9yIHkvbyB0aXR1bGFyIGF1dG9yaXphIGEgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEgcGFyYSBxdWUsIGVuIGxhIHJlcHJvZHVjY2nDs24geSBjb211bmljYWNpw7NuIGFsIHDDumJsaWNvIHF1ZSBsYSBVbml2ZXJzaWRhZCByZWFsaWNlIHNvYnJlIGxhIG9icmEsIGhhZ2EgbWVuY2nDs24gZGUgbWFuZXJhIGV4cHJlc2EgYWwgdGlwbyBkZSBsaWNlbmNpYSBDcmVhdGl2ZSBDb21tb25zIGJham8gbGEgY3VhbCBlbCBhdXRvciB5L28gdGl0dWxhciBkZXNlYSBvZnJlY2VyIHN1IG9icmEgYSBsb3MgdGVyY2Vyb3MgcXVlIGFjY2VkYW4gYSBkaWNoYSBvYnJhIGEgdHJhdsOpcyBkZWwgUmVwb3NpdG9yaW8gSW5zdGl0dWNpb25hbCwgY3VhbmRvIHNlYSBlbCBjYXNvLiBFbCBhdXRvciB5L28gdGl0dWxhciBkZSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciBwb2Ryw6EgZGFyIHBvciB0ZXJtaW5hZGEgbGEgcHJlc2VudGUgbGljZW5jaWEgbWVkaWFudGUgc29saWNpdHVkIGVsZXZhZGEgYSBsYSBEaXJlY2Npw7NuIE5hY2lvbmFsIGRlIEJpYmxpb3RlY2FzIGRlIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhLiAKCmIpIAlMb3MgYXV0b3JlcyB5L28gdGl0dWxhcmVzIGRlIGxvcyBkZXJlY2hvcyBwYXRyaW1vbmlhbGVzIGRlIGF1dG9yIHNvYnJlIGxhIG9icmEgY29uZmllcmVuIGxhIGxpY2VuY2lhIHNlw7FhbGFkYSBlbiBlbCBsaXRlcmFsIGEpIGRlbCBwcmVzZW50ZSBkb2N1bWVudG8gcG9yIGVsIHRpZW1wbyBkZSBwcm90ZWNjacOzbiBkZSBsYSBvYnJhIGVuIHRvZG9zIGxvcyBwYcOtc2VzIGRlbCBtdW5kbywgZXN0byBlcywgc2luIGxpbWl0YWNpw7NuIHRlcnJpdG9yaWFsIGFsZ3VuYS4KCmMpCUxvcyBhdXRvcmVzIHkvbyB0aXR1bGFyZXMgZGUgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciBtYW5pZmllc3RhbiBlc3RhciBkZSBhY3VlcmRvIGNvbiBxdWUgbGEgcHJlc2VudGUgbGljZW5jaWEgc2Ugb3RvcmdhIGEgdMOtdHVsbyBncmF0dWl0bywgcG9yIGxvIHRhbnRvLCByZW51bmNpYW4gYSByZWNpYmlyIGN1YWxxdWllciByZXRyaWJ1Y2nDs24gZWNvbsOzbWljYSBvIGVtb2x1bWVudG8gYWxndW5vIHBvciBsYSBwdWJsaWNhY2nDs24sIGRpc3RyaWJ1Y2nDs24sIGNvbXVuaWNhY2nDs24gcMO6YmxpY2EgeSBjdWFscXVpZXIgb3RybyB1c28gcXVlIHNlIGhhZ2EgZW4gbG9zIHTDqXJtaW5vcyBkZSBsYSBwcmVzZW50ZSBsaWNlbmNpYSB5IGRlIGxhIGxpY2VuY2lhIENyZWF0aXZlIENvbW1vbnMgY29uIHF1ZSBzZSBwdWJsaWNhLgoKZCkJUXVpZW5lcyBmaXJtYW4gZWwgcHJlc2VudGUgZG9jdW1lbnRvIGRlY2xhcmFuIHF1ZSBwYXJhIGxhIGNyZWFjacOzbiBkZSBsYSBvYnJhLCBubyBzZSBoYW4gdnVsbmVyYWRvIGxvcyBkZXJlY2hvcyBkZSBwcm9waWVkYWQgaW50ZWxlY3R1YWwsIGluZHVzdHJpYWwsIG1vcmFsZXMgeSBwYXRyaW1vbmlhbGVzIGRlIHRlcmNlcm9zLiBEZSBvdHJhIHBhcnRlLCAgcmVjb25vY2VuIHF1ZSBsYSBVbml2ZXJzaWRhZCBOYWNpb25hbCBkZSBDb2xvbWJpYSBhY3TDumEgY29tbyB1biB0ZXJjZXJvIGRlIGJ1ZW5hIGZlIHkgc2UgZW5jdWVudHJhIGV4ZW50YSBkZSBjdWxwYSBlbiBjYXNvIGRlIHByZXNlbnRhcnNlIGFsZ8O6biB0aXBvIGRlIHJlY2xhbWFjacOzbiBlbiBtYXRlcmlhIGRlIGRlcmVjaG9zIGRlIGF1dG9yIG8gcHJvcGllZGFkIGludGVsZWN0dWFsIGVuIGdlbmVyYWwuIFBvciBsbyB0YW50bywgbG9zIGZpcm1hbnRlcyAgYWNlcHRhbiBxdWUgY29tbyB0aXR1bGFyZXMgw7puaWNvcyBkZSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciwgYXN1bWlyw6FuIHRvZGEgbGEgcmVzcG9uc2FiaWxpZGFkIGNpdmlsLCBhZG1pbmlzdHJhdGl2YSB5L28gcGVuYWwgcXVlIHB1ZWRhIGRlcml2YXJzZSBkZSBsYSBwdWJsaWNhY2nDs24gZGUgbGEgb2JyYS4gIAoKZikJQXV0b3JpemFuIGEgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEgaW5jbHVpciBsYSBvYnJhIGVuIGxvcyBhZ3JlZ2Fkb3JlcyBkZSBjb250ZW5pZG9zLCBidXNjYWRvcmVzIGFjYWTDqW1pY29zLCBtZXRhYnVzY2Fkb3Jlcywgw61uZGljZXMgeSBkZW3DoXMgbWVkaW9zIHF1ZSBzZSBlc3RpbWVuIG5lY2VzYXJpb3MgcGFyYSBwcm9tb3ZlciBlbCBhY2Nlc28geSBjb25zdWx0YSBkZSBsYSBtaXNtYS4gCgpnKQlFbiBlbCBjYXNvIGRlIGxhcyB0ZXNpcyBjcmVhZGFzIHBhcmEgb3B0YXIgZG9ibGUgdGl0dWxhY2nDs24sIGxvcyBmaXJtYW50ZXMgc2Vyw6FuIGxvcyByZXNwb25zYWJsZXMgZGUgY29tdW5pY2FyIGEgbGFzIGluc3RpdHVjaW9uZXMgbmFjaW9uYWxlcyBvIGV4dHJhbmplcmFzIGVuIGNvbnZlbmlvLCBsYXMgbGljZW5jaWFzIGRlIGFjY2VzbyBhYmllcnRvIENyZWF0aXZlIENvbW1vbnMgeSBhdXRvcml6YWNpb25lcyBhc2lnbmFkYXMgYSBzdSBvYnJhIHBhcmEgbGEgcHVibGljYWNpw7NuIGVuIGVsIFJlcG9zaXRvcmlvIEluc3RpdHVjaW9uYWwgVU5BTCBkZSBhY3VlcmRvIGNvbiBsYXMgZGlyZWN0cmljZXMgZGUgbGEgUG9sw610aWNhIEdlbmVyYWwgZGUgbGEgQmlibGlvdGVjYSBEaWdpdGFsLgoKCmgpCVNlIGF1dG9yaXphIGEgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEgY29tbyByZXNwb25zYWJsZSBkZWwgdHJhdGFtaWVudG8gZGUgZGF0b3MgcGVyc29uYWxlcywgZGUgYWN1ZXJkbyBjb24gbGEgbGV5IDE1ODEgZGUgMjAxMiBlbnRlbmRpZW5kbyBxdWUgc2UgZW5jdWVudHJhbiBiYWpvIG1lZGlkYXMgcXVlIGdhcmFudGl6YW4gbGEgc2VndXJpZGFkLCBjb25maWRlbmNpYWxpZGFkIGUgaW50ZWdyaWRhZCwgeSBzdSB0cmF0YW1pZW50byB0aWVuZSB1bmEgZmluYWxpZGFkIGhpc3TDs3JpY2EsIGVzdGFkw61zdGljYSBvIGNpZW50w61maWNhIHNlZ8O6biBsbyBkaXNwdWVzdG8gZW4gbGEgUG9sw610aWNhIGRlIFRyYXRhbWllbnRvIGRlIERhdG9zIFBlcnNvbmFsZXMuCgoKClBBUlRFIDIuIEFVVE9SSVpBQ0nDk04gUEFSQSBQVUJMSUNBUiBZIFBFUk1JVElSIExBIENPTlNVTFRBIFkgVVNPIERFIE9CUkFTIEVOIEVMIFJFUE9TSVRPUklPIElOU1RJVFVDSU9OQUwgVU5BTC4KClNlIGF1dG9yaXphIGxhIHB1YmxpY2FjacOzbiBlbGVjdHLDs25pY2EsIGNvbnN1bHRhIHkgdXNvIGRlIGxhIG9icmEgcG9yIHBhcnRlIGRlIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHkgZGUgc3VzIHVzdWFyaW9zIGRlIGxhIHNpZ3VpZW50ZSBtYW5lcmE6CgphLglDb25jZWRvIGxpY2VuY2lhIGVuIGxvcyB0w6lybWlub3Mgc2XDsWFsYWRvcyBlbiBsYSBwYXJ0ZSAxIGRlbCBwcmVzZW50ZSBkb2N1bWVudG8sIGNvbiBlbCBvYmpldGl2byBkZSBxdWUgbGEgb2JyYSBlbnRyZWdhZGEgc2VhIHB1YmxpY2FkYSBlbiBlbCBSZXBvc2l0b3JpbyBJbnN0aXR1Y2lvbmFsIGRlIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHkgcHVlc3RhIGEgZGlzcG9zaWNpw7NuIGVuIGFjY2VzbyBhYmllcnRvIHBhcmEgc3UgY29uc3VsdGEgcG9yIGxvcyB1c3VhcmlvcyBkZSBsYSBVbml2ZXJzaWRhZCBOYWNpb25hbCBkZSBDb2xvbWJpYSAgYSB0cmF2w6lzIGRlIGludGVybmV0LgoKCgpQQVJURSAzIEFVVE9SSVpBQ0nDk04gREUgVFJBVEFNSUVOVE8gREUgREFUT1MgUEVSU09OQUxFUy4KCkxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhLCBjb21vIHJlc3BvbnNhYmxlIGRlbCBUcmF0YW1pZW50byBkZSBEYXRvcyBQZXJzb25hbGVzLCBpbmZvcm1hIHF1ZSBsb3MgZGF0b3MgZGUgY2Fyw6FjdGVyIHBlcnNvbmFsIHJlY29sZWN0YWRvcyBtZWRpYW50ZSBlc3RlIGZvcm11bGFyaW8sIHNlIGVuY3VlbnRyYW4gYmFqbyBtZWRpZGFzIHF1ZSBnYXJhbnRpemFuIGxhIHNlZ3VyaWRhZCwgY29uZmlkZW5jaWFsaWRhZCBlIGludGVncmlkYWQgeSBzdSB0cmF0YW1pZW50byBzZSByZWFsaXphIGRlIGFjdWVyZG8gYWwgY3VtcGxpbWllbnRvIG5vcm1hdGl2byBkZSBsYSBMZXkgMTU4MSBkZSAyMDEyIHkgZGUgbGEgUG9sw610aWNhIGRlIFRyYXRhbWllbnRvIGRlIERhdG9zIFBlcnNvbmFsZXMgZGUgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEuIFB1ZWRlIGVqZXJjZXIgc3VzIGRlcmVjaG9zIGNvbW8gdGl0dWxhciBhIGNvbm9jZXIsIGFjdHVhbGl6YXIsIHJlY3RpZmljYXIgeSByZXZvY2FyIGxhcyBhdXRvcml6YWNpb25lcyBkYWRhcyBhIGxhcyBmaW5hbGlkYWRlcyBhcGxpY2FibGVzIGEgdHJhdsOpcyBkZSBsb3MgY2FuYWxlcyBkaXNwdWVzdG9zIHkgZGlzcG9uaWJsZXMgZW4gd3d3LnVuYWwuZWR1LmNvIG8gZS1tYWlsOiBwcm90ZWNkYXRvc19uYUB1bmFsLmVkdS5jbyIKClRlbmllbmRvIGVuIGN1ZW50YSBsbyBhbnRlcmlvciwgYXV0b3Jpem8gZGUgbWFuZXJhIHZvbHVudGFyaWEsIHByZXZpYSwgZXhwbMOtY2l0YSwgaW5mb3JtYWRhIGUgaW5lcXXDrXZvY2EgYSBsYSBVbml2ZXJzaWRhZCBOYWNpb25hbCBkZSBDb2xvbWJpYSBhIHRyYXRhciBsb3MgZGF0b3MgcGVyc29uYWxlcyBkZSBhY3VlcmRvIGNvbiBsYXMgZmluYWxpZGFkZXMgZXNwZWPDrWZpY2FzIHBhcmEgZWwgZGVzYXJyb2xsbyB5IGVqZXJjaWNpbyBkZSBsYXMgZnVuY2lvbmVzIG1pc2lvbmFsZXMgZGUgZG9jZW5jaWEsIGludmVzdGlnYWNpw7NuIHkgZXh0ZW5zacOzbiwgYXPDrSBjb21vIGxhcyByZWxhY2lvbmVzIGFjYWTDqW1pY2FzLCBsYWJvcmFsZXMsIGNvbnRyYWN0dWFsZXMgeSB0b2RhcyBsYXMgZGVtw6FzIHJlbGFjaW9uYWRhcyBjb24gZWwgb2JqZXRvIHNvY2lhbCBkZSBsYSBVbml2ZXJzaWRhZC4gCgo=

Publicaciones similares